| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.22 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.38 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.25 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.25 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.43 | KE:1023 | Increased, Thyroid-stimulating hormone (TSH) |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Zebrafish | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.09 | KE:10042 | Abnormal development | |
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:386 | Decrease of neuronal network function |
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.25 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.33 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.2 | KE:2066 | Altered Signaling Pathways |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:381 | Reduced levels of BDNF |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.4 | KE:386 | Decrease of neuronal network function |
| KE:385 | Decrease of synaptogenesis | ||||||
| KE:381 | Reduced levels of BDNF | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.2 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.11 | KE:341 | Impairment, Learning and memory |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:1101 | Altered, Amphibian metamorphosis |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.8 | KE:425 | Decrease of Thyroidal iodide |
| KE:1101 | Altered, Amphibian metamorphosis | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:189 | Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1101 | Altered, Amphibian metamorphosis | ||||||
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1101 | Altered, Amphibian metamorphosis | ||||||
| KE:1023 | Increased, Thyroid-stimulating hormone (TSH) | ||||||
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:1101 | Altered, Amphibian metamorphosis |
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:1101 | Altered, Amphibian metamorphosis |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:1101 | Altered, Amphibian metamorphosis |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.33 | KE:1101 | Altered, Amphibian metamorphosis |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development | |
| AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:1101 | Altered, Amphibian metamorphosis | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:1101 | Altered, Amphibian metamorphosis | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.25 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.09 | KE:341 | Impairment, Learning and memory | |
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:341 | Impairment, Learning and memory |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.08 | KE:341 | Impairment, Learning and memory | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.67 | KE:386 | Decrease of neuronal network function | |
| KE:851 | Decrease of GABAergic interneurons | ||||||
| KE:385 | Decrease of synaptogenesis | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:341 | Impairment, Learning and memory |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.57 | KE:1023 | Increased, Thyroid-stimulating hormone (TSH) |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:424 | Inhibition, Na+/I- symporter (NIS) | ||||||
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.18 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.56 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:425 | Decrease of Thyroidal iodide | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:424 | Inhibition, Na+/I- symporter (NIS) | ||||||
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 1.0 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:425 | Decrease of Thyroidal iodide | ||||||
| KE:424 | Inhibition, Na+/I- symporter (NIS) | ||||||
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased | ||||||
| KE:381 | Reduced levels of BDNF | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:385 | Decrease of synaptogenesis | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| KE:851 | Decrease of GABAergic interneurons | ||||||
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 1.0 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:425 | Decrease of Thyroidal iodide | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:424 | Inhibition, Na+/I- symporter (NIS) | ||||||
| KE:1101 | Altered, Amphibian metamorphosis |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.